Glaxo (GSK) Could Bid $25/Share for Human Genome (HGSI) -UK's Mail
Tweet
Share
E-mail
Get Alerts HGSI Hot Sheet
Join SI Premium – FREE
Shares of Human Genome Sciences (Nasdaq: HGSI) are up nearly 7 percent in pre-market action Tuesday amid chatter out of the UK's Mail.
Rumors suggest GlaxoSmithKline (NYSE: GSK) could bid as much as $25 per share in cash for Human Genome. The article points out the two companies already partner for Benlysta.
With Human Genome shares last trading around $12, the rumored price would indicate a more than 100 percent premium.
Notably, shares of Human Genome Sciences have fallen nearly 50 percent over the last two months.
Rumors suggest GlaxoSmithKline (NYSE: GSK) could bid as much as $25 per share in cash for Human Genome. The article points out the two companies already partner for Benlysta.
With Human Genome shares last trading around $12, the rumored price would indicate a more than 100 percent premium.
Notably, shares of Human Genome Sciences have fallen nearly 50 percent over the last two months.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Trustar Bank to acquire Forbright Bank branches for $750M in deposits
- Forbright Bank to sell branches and deposits to Trustar Bank
Create E-mail Alert Related Categories
Mergers and Acquisitions, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
